Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 2;10(4):787.
doi: 10.3390/cells10040787.

Artificial Intelligence & Tissue Biomarkers: Advantages, Risks and Perspectives for Pathology

Cesare Lancellotti  1   2 , Pierandrea Cancian  3 , Victor Savevski  3 , Soumya Rupa Reddy Kotha  1   2 , Filippo Fraggetta  4 , Paolo Graziano  5 , Luca Di Tommaso  1   2
Affiliations
Review

Artificial Intelligence & Tissue Biomarkers: Advantages, Risks and Perspectives for Pathology

Cesare Lancellotti et al. Cells. .

Abstract

Tissue Biomarkers are information written in the tissue and used in Pathology to recognize specific subsets of patients with diagnostic, prognostic or predictive purposes, thus representing the key elements of Personalized Medicine. The advent of Artificial Intelligence (AI) promises to further reinforce the role of Pathology in the scenario of Personalized Medicine: AI-based devices are expected to standardize the evaluation of tissue biomarkers and also to discover novel information, which would otherwise be ignored by human review, and use them to make specific predictions. In this review we will present how AI has been used to support Tissue Biomarkers evaluation in the specific field of Pathology, give an insight to the intriguing field of AI-based biomarkers and discuss possible advantages, risk and perspectives for Pathology.

Keywords: artificial intelligence; biomarker; pathology; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Development of an AI-based biomarker. The AI model is fed by input data (huge collection of clinical information and digital images) and learns the optimal feature to best separate the categories of interest, without pre-existing assumptions. The classification outcome returns an information of significant clinical impact in the diagnosis, prognosis or prediction.
See this image and copyright information in PMC

References

    1. Colling R., Pitman H., Oien K., Rajpoot N., Macklin P., CM-Path AI in Histopathology Working Group. Bachtiar V., Booth R., Bryant A., Bull J., et al. Artificial intelligence in digital pathology: A roadmap to routine use in clinical practice. J. Pathol. 2019;249:143–150. doi: 10.1002/path.5310. - DOI - PubMed
    1. Parwani A.V., Amin M.B. Convergence of Digital Pathology and Artificial Intelligence Tools in Anatomic Pathology Practice: Current Landscape and Future Directions. Adv. Anat. Pathol. 2020;27:221–226. doi: 10.1097/PAP.0000000000000271. - DOI - PubMed
    1. Niazi M.K., Parwani A.V., Gurcan M.N. Digital pathology and artificial intelligence. Lancet Oncol. 2019;20:e253–e261. doi: 10.1016/S1470-2045(19)30154-8. - DOI - PMC - PubMed
    1. Ponzio F., Urgese G., Ficarra E., Di Cataldo S. Dealing with Lack of Training Data for Convolutional Neural Networks: The Case of Digital Pathology. Electronics. 2019;8:256. doi: 10.3390/electronics8030256. - DOI
    1. Mormont R., Geurts P., Marée R. Comparison of deep transfer learning strategies for digital pathology; Proceedings of the 2018 IEEE Conference on Computer Vision and Pattern Recognition Workshops (CVPRW); Salt Lake City, UT, USA. 18–22 June 2018.

Publication types

LinkOut - more resources